Amivantamab-Based Regimens Show Anticancer Activity in EGFR-Mutated Advanced NSCLC – The ASCO Post
Widely anticipated findings from the MARIPOSA1 and MARIPOSA-22 trials were presented at the European Society for Medical Oncology (ESMO) Congress 2023, showing potentially improved outcomes with regimens incorporating the bispecific antibody amivantamab-vmjw for patients with advanced non–small cell lung cancer (NSCL) and epidermal growth factor receptor (EGFR) mutations. The studies were…